Table SII. Univariate analysis: SSc patients' factors associated with venous lowerlimb ulcers (LLUs)

Factor	Venous n = 22	Controls $n = 44$	<i>p</i> -value
Gender			
Female/Male, n	21/1	42/2	> 0.9999
Age at last follow-up, years, mean (range)	66.4 (38-87)	65.4 (36-87)	0.7131
Cardiovascular risk factor(s), n	,	` ,	
≥1	15	22	0.1898
≥2	4	5	0.4734
Obesity, n	1	3	> 0.9999
History of deep venous thrombosis, <i>n</i>	6	2	0.0137
Age at SSc diagnosis, years , mean (range)	51.9 (26-72)	56.1 (31-81)	0.3987
SSc diagnosis to last follow-up, months, mean (range)	175 (19-420)	115 (0-395)	0.0653
SSc subset, n			
Diffuse cutaneous SSc	0	3	0.5452
Limited cutaneous SSc	21	33	0.0488
Sine scleroderma SSc	1	8	0.2525
Skin sclerosis localization, n			
Trunk	6	3	0.0506
Hand	1	4	0.6577
Foot	21	35	0.1459
Leg	4	3	0.2100
History of digital ulcer, n	13	20	0.2148
History of cutaneous calcification, n	11	9	0.0138
Toe Raynaud's phenomenon, n	5	11	0.8391
Visceral involvement of SSc, n			
Gastrointestinal	14	20	0.1635
Pulmonary artery hypertension	6	1	0.0044
Pulmonary fibrosis	11	9	0.0138
Cardiac	2	0	0.2558
Antibodies, n			
Anti-centromere	12	27	0.5954
Anti- topoisomerase-I	3	8	0.7390
Biologic prothrombotic factors ^{a,b} , n	3/27 (23)	3/13 (11)	0.3699
Cryoglobulinemia ^a , <i>n</i>	1/10 (10)	0/11	0.2143
Nailfold capillaroscopy, n			
Quantitative abnormalities ^{a,c} , n	12/15	25/40	0.3353
Qualitative abnormalities ^{a,d} , n	12/15	36/40	0.3758

Data are expressed as numbers (%) or means (range) (%) unless stated otherwise.

aNumber of patients for whom information was available/number of patients.

bAnti-phospholipid, anti-cardiolipin, anti-β2-glycoprotein1 antibodies or lupus anticoagulant.

cAvascular areas (< 2 capillary loops over a length of 1mm), capillary loss (< 7 loops/mm), and disorganization of the microvascular array.

dPresence of glant capillaries (diameter ≥50 µm) and/or bushy capillaries.